Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: serious adverse events ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Any serious adverse event of treatment count of events · people with traumatic head injuries
Antiepileptic drugs showed no clear difference in any serious adverse event of treatment count of events compared with placebo or standard care (low certainty).
1 finding from 1 review
Serious adverse events (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in serious adverse events (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Any serious or non‐serious adverse event · Individuals with autism spectrum disorder
Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Serious adverse events during the study period · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).
1 finding from 1 review
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Mortality or serious adverse events requiring hospital admission · Adults or children at increased risk of bacterial endocarditis (pre-existing cardiac condition) undergoing an invasive dental procedure
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ serious infection compared with placebo compared (high certainty).
1 finding from 1 review
Adverse events (serious adverse reaction and adverse reaction) · children and adults with CF
Probiotics showed no clear difference in adverse events (serious adverse reaction and adverse reaction) compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review